 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||||| botulinum toxin type A (ATGC-110) / ATGC Co
Enrollment closed: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin (clinicaltrials.gov) - Feb 3, 2023
P3, N=300, Active, not recruiting, Sponsor: ATGC Co., Ltd.
Recruiting --> Active, not recruiting
- |||||||||| botulinum toxin type A (ATGC-110) / ATGC Co
New P3 trial: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin (clinicaltrials.gov) - Nov 21, 2022
P3, N=300, Recruiting, Sponsor: ATGC Co., Ltd.
- ||||||| Eutox (botulinum toxin type A) / ATGC Co, EuBiologics
Trial completion, Head-to-Head: Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines (clinicaltrials.gov) - Apr 4, 2022
P3, N=290, Completed, Sponsor: EuBiologics Co.,Ltd
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Eutox (botulinum toxin type A) / ATGC Co, EuBiologics
New P3 trial, Head-to-Head: Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines (clinicaltrials.gov) - Apr 4, 2021
P3, N=290, Active, not recruiting, Sponsor: EuBiologics Co.,Ltd
- ||| Eutox (botulinum toxin type A) / ATGC Co, EuBiologics
Trial completion, Head-to-Head: Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects (clinicaltrials.gov) - Mar 23, 2021
P1/2, N=60, Completed, Sponsor: EuBiologics Co.,Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| botulinum toxin type A (ATGC-110) / ATGC Co
Trial completion: A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=60, Completed, Sponsor: ATGC Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | botulinum toxin type A (ATGC-110) / ATGC Co
New P1/2 trial: A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - Feb 24, 2020
P1/2, N=60, Active, not recruiting, Sponsor: ATGC Co., Ltd.
- |||| Eutox (botulinum toxin type A) / ATGC Co, EuBiologics
New P1/2 trial, Head-to-Head: Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects (clinicaltrials.gov) - Jun 2, 2019
P1/2, N=60, Active, not recruiting, Sponsor: EuBiologics Co.,Ltd